Novavax (NSDQ:NVAX) today announced that it has begun its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate, NVX-CoV2373.
The trial is underway in the UK, in partnership with the UK government’s Vaccines Taskforce. Gaithersburg, Md.-based Novavax said it expects to enroll up to 10,000 individuals between 18 and 84 years of age, with and without relevant comorbidities, over the next four to six weeks and to make its UK study protocol public “in the coming days.”
Get the full story on our sister site, Drug Discovery & Development.